TAFAZZIN and Hyperglycemia: Cole et al. (2021) recently elucidated the cause of this hyperglycemia, identifying impaired insulin secretion during basal conditions (i.e., unstimulated low-glucose conditions) in Taz-KD mice, despite equivalent fold-increases in glucose-stimulated insulin secretion [66].